The proportion of patients with low IL‐6 level (<4.285 pg/mL) in the subgroup who undergone tumor relapse during consolidation therapy within 2 years was decreased compared with those who maintained long‐term CR after treatment cessation for over 2 years (Figure 4C). The gene discussed is IL6; the disease is neoplasm.